Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 16/20 | 0.69 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.69 |
| ▸ | CDK2 | P24941 | 5/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.69 |
| ▸ | GSK3A | P49840 | 4/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.62 |
| ▸ | CDK1 | P06493 | 3/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.62 |
| ▸ | ABL2 | P42684 | 3/20 | 0.62 |
| ▸ | CDK4 | P11802 | 2/20 | 0.62 |
| ▸ | CCND1 | P24385 | 2/20 | 0.62 |
| ▸ | CDK7 | P50613 | 2/20 | 0.62 |
| ▸ | CCNH | P51946 | 2/20 | 0.62 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109342 | 0.92 | CDK9 (0.67) | CDK9CCNT1CDK2CCNE1GSK3A | |
| SCHEMBL4101973 | 0.89 | CDK9 (0.82) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL8516163 | 0.88 | CDK9 (0.81) | CDK9CCNT1CDK2CCNE1GSK3A | |
| SCHEMBL4104753 | 0.84 | CDK9 (0.59) | CDK9CCNT1CDK2CCNE1GSK3A | |
| SCHEMBL2030393 | 0.84 | CDK9 (0.63) | CDK9CCNT1CDK2CCNE1GSK3A | |
| SCHEMBL4426442 | 0.82 | CDK9 (0.82) | CDK9CCNT1CDK2CCNE1GSK3A | |
| SCHEMBL8515993 | 0.81 | CDK9 (0.66) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL4108822 | 0.80 | CDK9 (0.65) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL4108973 | 0.80 | CDK9 (1.00) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL4103640 | 0.80 | CDK9 (0.76) | CDK9CCNT1CDK2GSK3AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| US-8084457-B2 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | LEAD DISCOVERY CENTER GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | DAPK1, DUSP4, MARK4 | CDK9 137/4885CCNT1 2075/4885CDK2 266/4885 |
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | CDK9 97/4885CCNT1 81/4885CDK2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.